Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000492

Drug Information
SynonymsKBioGR_000794; Prestwick1_000129; NCGC00024297-05; MolPort-002-673-624; NCGC00015836-09; Spectrum2_001417; Gasteril; L-S 519; Pirenzepina; KBio3_002445; Prestwick2_000129; Spectrum3_001453; Pirenzepine (INN); Pirenzepinum; KBio2_004426; Lopac-P-7412; DB00670; Prestwick3_000129; 6H-Pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((4-methyl-1-piperazinyl)acetyl)-; KBio2_001858; NCGC00024297-04; LS-133128; AC1L1J3B; DivK1c_000127; Bio-0807; Prestwick0_000129; Pirenzepine [INN:BAN]; Ulcosan; Gastrozepin; NCGC00015836-01; D08389; Pirenzepinum [INN-Latin]; L000485; NCGC00015836-02; AB00053603; NCGC00024297-02; 28797-61-7; BSPBio_000178; CHEBI:8247; UNII-3G0285N20N; KBio2_006994; Pyrenzepine; SPBio_001494; KBio1_000127; IDI1_000127; EINECS 249-228-4; PDSP1_000965; NINDS_000127; BPBio1_000196; HMS2089K21; Spectrum4_000437; Pirenzepine Gastrozepin; 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; Gastrotsepin; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]-; NCGC00015836-03; Tocris-1071; C07508; Pirenzepina [INN-Spanish]; CID4848; CHEMBL9967; Spectrum5_001344; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; PDSP2_000949; Pirenzepin; Lopac0_000962; BRN 0628987; BSPBio_002945; Spectrum_001378; KBioSS_001858; BRD-K89375097-300-05-4; C19H21N5O2; SPBio_002117; pirenzepine; CAS-29868-97-1    
Trade NameGastrozepin    
CompanyBoehringer Ingelheim    
IndicationPeptic ulcer diseaseApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnti-Ulcer Agents    
CAS NumberCAS 28797-61-7
PubChem Compound IDCID 4848.    
PubChem Substance IDSID 9711.    
SuperDrug ATC IDA02BX03;    
SuperDrug CAS ID028797617;    
TargetMuscarinic acetylcholine receptor M1Antagonist[2][3]
Ref 1Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade. J Cardiovasc Pharmacol. 2003 May;41(5):671-7. To Reference
Ref 2Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31. Epub 2009 May 7. To Reference
Ref 3The effect of muscarinic receptor blockers on non-specific bronchial reactivity in patients with bronchial asthma. Pneumonol Alergol Pol. 1992;60(11-12):32-6. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543